Effect of prior statin use on functional outcome and delayed vasospasm after acute aneurysmal subarachnoid hemorrhage: A matched controlled cohort study

Neurosurgery

Volumn 56, Issue 3, 2005, Pages 476-483

  Parra, Augusto ^a   Kreiter, Kurt T ^a   Williams, Susan ^a   Sciacca, Robert ^a   Mack, William J ^a   Naidech, Andrew M ^a   Commichau, Christopher S ^a   Fitzsimmons, Brian Fred M ^a   Janjua, Nazli ^a   Mayer, Stephan A ^a   Connolly Jr , E Sander ^a  

^a Columbia Univ Coll of Phys Surgs ^*  (United States)

Author keywords

Functional outcome; Statins; Subarachnoid hemorrhage; Vasospasm

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGED; ARTICLE; BARTHEL INDEX; BRAIN ANGIOGRAPHY; BRAIN ARTERY ANEURYSM; BRAIN INFARCTION; BRAIN ISCHEMIA; BRAIN VASOSPASM; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DOPPLER ECHOGRAPHY; DRUG EFFECT; FEMALE; FUNCTIONAL ASSESSMENT; HOSPITALIZATION; HUMAN; MALE; MORTALITY; NEUROPROTECTION; PRIORITY JOURNAL; RANKIN SCALE; RISK REDUCTION; SCORING SYSTEM; STROKE; SUBARACHNOID HEMORRHAGE; TREATMENT OUTCOME;

ADULT; AGED; ANEURYSM, RUPTURED; BRAIN ISCHEMIA; CEREBRAL ANGIOGRAPHY; CEREBRAL INFARCTION; COHORT STUDIES; COMORBIDITY; DRUG EVALUATION; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INCIDENCE; INTRACRANIAL ANEURYSM; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SUBARACHNOID HEMORRHAGE; TREATMENT OUTCOME; VASOSPASM, INTRACRANIAL;

EID: 20044362739     PISSN: 0148396X     EISSN: None     Source Type: Journal    
DOI: 10.1227/01.NEU.0000153925.96889.8A     Document Type: Article

References (62)

1. Aihara Y, Jahromi BS, Yassari R, Sayama T, Macdonald RL: Effects of a nitric oxide donor on and correlation of changes in cyclic nucleotide levels with experimental vasospasm. Neurosurgery 52:661-667, 2003.
2. Amin-Hanjani S, Stagliano NE, Yamada M, Huang PL, Liao JR, Moskowitz MA: Mevastatin, an HMG-CoA reductase inhibitor, reduces stroke damage and upregulates endothelial nitric oxide synthase in mice. Stroke 32:980-986, 2001.
3. ATP III Final Report: II - Rationale for intervention. Circulation 106:3163-3223, 2002.
4. Balduini W, De Angelis V, Mazzoni E, Cimino M: Simvastatin protects against long-lasting behavioral and morphological consequences of neonatal hypoxic/ischemic brain injury. Stroke 32:2185-2191, 2001.
5. Bivalacqua TJ, Usta MF, Champion HC, Adams D, Namara DB, Abdel-Mageed AB, Kadowitz PJ, Hellstrom NJ: Gene transfer of endothelial nitric oxide synthase partially restores nitric oxide synthesis and erectile function in streptozotocin diabetic rats. J Urol 169:1911-1917, 2003.
6. Brouet A, Sonveaux P, Dessy C, Moniotte S, Balligand JL, Feron O: Hsp90 and caveolin are key targets for the proangiogenic nitric oxide-mediated effects of statins. Circ Res 89:866-873, 2001.
7. Claassen J, Bernardini GL, Kreiter K, Bates J, Du YE, Copeland D, Connolly ES, Mayer SA: Effect of cisternal and ventricular blood on risk of delayed cerebral ischemia after subarachnoid hemorrhage: The Fisher Scale revisited. Stroke 32:2012-2020, 2001.
8. Degraeve F, Bolla M, Blaie S, Creminon C, Quere I, Boquet P, Levy-Toledano S, Bertoglio J, Habib A: Modulation of COX-2 expression by statins in human aortic smooth muscle cells: Involvement of geranylgeranylated proteins. J Biol Chem 276:46849-46855, 2001.
9. Delanty N, Vaughan CJ: Vascular effects of statins in stroke. Stroke 28:2315-2320, 1997.
10. Dimmeler S, Haendeler J, Zeiher AM: Regulation of endothelial cell apoptosis in atherothrombosis. Curr Opin Lipidol 13:531-536, 2002.
11. Dumont AS, Dumont RJ, Chow MM, Lin CL, Calisaneller T, Lay KF, Kassell NF, Lee KS: Cerebral vasospasm after subarachnoid hemorrhage: Putative role of inflammation. Neurosurgery 53:123-135, 2003.
12. Duncan PW, Lai SM, Tyler D, Perera S, Reker DM, Studenski S: Evaluation of proxy responses to the Stroke Impact Scale. Stroke 33:2593-2599, 2002.
13. Eriksson A, Cao R, Roy J, Tritsaris K, Wahlestedt C, Dissing S, Thyberg J, Cao Y: Small GTP-binding protein Rac is an essential mediator of vascular endothelial growth factor-induced endothelial fenestrations and vascular permeability. Circulation 107:1532-1538, 2003.
14. Frenette PS: Locking a leukocyte integrin with statins. N Engl J Med 345:1419-1421, 2001.
15. Gabikian P, Clatterbuck RE, Eberhart CG, Tyler BM, Tierney TS, Tamargo RJ: Prevention of experimental cerebral vasospasm by intracranial delivery of a nitric oxide donor from a controlled-release polymer: Toxicity and efficacy studies in rabbits and rats. Stroke 33:2681-2686, 2002.
16. Gertz K, Laufs U, Lindauer U, Nickenig G, Bohm M, Dirnagl U, Endres M: Withdrawal of statin treatment abrogates stroke protection in mice. Stroke 34:551-557, 2003.
17. Gorelick PB: Stroke prevention therapy beyond antithrombotics: Unifying mechanisms in ischemic stroke pathogenesis and implications for therapy - An invited review. Stroke 33:862-875, 2002.
18. Heeschen C, Hamm CW, Laufs U, Snapinn S, Bohm M, White HD: Withdrawal of statins increases event rates in patients with acute coronary syndromes. Circulation 105:1446-1452, 2002.
19. Hijdra A, Brouwers PJ, Vermeulen M, van Gijn J: Grading the amount of blood on computed tomograms after subarachnoid hemorrhage. Stroke 21:1156-1161, 1990.
20. Hop JW, Rinkel GJ, Algra A, van Gijn J: Initial loss of consciousness and risk of delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage. Stroke 30:2268-2271, 1999 (comment).
21. Hunt WE, Hess RM: Surgical risk as related to time of intervention in the repair of intracranial aneurysms. J Neurosurg 28:14-20, 1968.
22. Inoha S, Inamura T, Ikezaki K, Nakamizo A, Amano T, Fukui M: Type V phosphodiesterase expression in cerebral arteries with vasospasm after subarachnoid hemorrhage in a canine model. Neurol Res 24:607-612, 2002.
23. Islam MS, Ohkuma H, Kimura M, Suzuki S: In vitro effects of new generation fungal derived nitric oxide donors on rabbit basilar artery. Neurol Med Chir (Tokyo) 43:175-180, 2003.
24. Jonsson N, Asplund K: Does pretreatment with statins improve clinical outcome after stroke? A pilot case-referent study. Stroke 32:1112-1115, 2001.
25. Karpiuk VB, Shubich MG: Perspectives of pharmacological correction of nitroxidergic vasorelaxation in subarachnoidal hemorrhage [in Russian]. Zh Vopr Neirokhir Im N N Burdenko 2:56-61, 2002.
26. Kawashima S, Yamashita T, Miwa Y, Ozaki M, Namiki M, Ukase T, Inoue N, Hirata K, Yokoyama M: HMG-CoA reductase inhibitor has protective effects against stroke events in stroke-prone spontaneously hypertensive rats. Stroke 34:157-163, 2003.
27. Kissela BM, Sauerbeck L, Woo D, Khoury J, Carrozzella J, Pancioli A, Jauch E, Moomaw Q, Shukla P., Gebel J, Fontaine R, Broderick J: Subarachnoid hemorrhage: A preventable disease with a heritable component. Stroke 33:1321-1326, 2002.
28. Kistler JP, Crowell RM, Davis KR, Heros R, Ojemann RG, Zervas T, Fisher CM: The extent and location of subarachnoid blood visualized by CT scan: A prospective study. Neurology 33:424-436, 1983.
29. Kreiter KT, Copeland D, Bernardini GL, Bates JE, Peery S, Claassen J, Du YE, Stern Y, Connolly ES, Mayer SA: Predictors of cognitive dysfunction after subarachnoid hemorrhage. Stroke 33:200-209, 2002.
30. Laufs U, Endres M, Custodis F, Gertz K, Nickenig G, Liao JK, Bohm M: Suppression of endothelial nitric oxide production after withdrawal of statin treatment is mediated by negative feedback regulation of rho GTPase gene transcription. Circulation 102:3104-3110, 2000.
31. Laufs U, Gertz K, Huang P, Nickenig G, Bohm M, Dirnagl U, Endres M: Atorvastatin upregulates type III nitric oxide synthase in thrombocytes, decreases platelet activation, and protects from cerebral ischemia in normocholesterolemic mice. Stroke 31:2442-2449, 2000.
32. Lawton MP: Scales to measure competence in everyday activities. Psychopharmacol Bull 24:609-614, 1988.
33. Ledoux S, Laouari D, Essig M, Runembert I, Trugnan G, Michel JB, Friedlander G: Lovastatin enhances ecto-5′-nucleotidase activity and cell surface expression in endothelial cells: Implication of rho-family GTPases. Circ Res 90:420-427, 2002.
34. Longstreth WT Jr, Nelson LM, Koepsell TD, van Belle G: Clinical course of spontaneous subarachnoid hemorrhage: A population-based study in King County, Washington. Neurology 43:712-718, 1993 (comment).
35. Loscalzo J: Nitric oxide insufficiency, platelet activation, and arterial thrombosis. Circ Res 88:756-762, 2001.
36. Magyar MT, Szikszai Z, Balla J, Valikovics A, Kappelmayer J, Imre S, Balla G, Jeney V, Csiba L, Bereczki D: Early-onset carotid atherosclerosis is associated with increased intima-media thickness and elevated serum levels of inflammatory markers. Stroke 34:58-63, 2003.
37. Maron DJ, Fazio S, Linton MF: Current perspectives on statins. Circulation 101:207-213, 2000.
38. Massy ZA, Guijarro C: Statins: Effects beyond cholesterol lowering. Nephrol Dial Transpl 16:1738-1741, 2001.
39. Mayer SA, Kreiter KT, Copeland D, Bernardini GL, Bates JE, Peery S, Claassen J, Du YE, Connolly ES Jr: Global and domain-specific cognitive impairment and outcome after subarachnoid hemorrhage. Neurology 59:1750-1758, 2002.
40. McGirt MJ, Lynch JR, Parra A, Sheng H, Pearlstein RD, Laskowitz DT, Pelligrino DA, Warner DS: Simvastatin increases endothelial nitric oxide synthase and ameliorates cerebral vasospasm resulting from subarachnoid hemorrhage. Stroke 33:2950-2956, 2002.
41. McGirt MJ, Mavropoulos JC, McGirt LY, Alexander MJ, Friedman AH, Laskowitz DT, Lynch JR: Leukocytosis as an independent risk factor for cerebral vasospasm following aneurysmal subarachnoid hemorrhage. J Neurosurg 98:1222-1226, 2003.
42. McGirt MJ, Parra A, Sheng H, Higuchi Y, Oury TD, Laskowitz DT, Pearlstein RD, Warner DS: Attenuation of cerebral vasospasm after subarachnoid hemorrhage in mice overexpressing extracellular superoxide dismutase. Stroke 33:2317-2323, 2002.
43. Ni W, Egashira K, Kataoka C, Kitamoto S, Kozanagi M, Inoue S, Takeshita A: Anti-inflammatory and anti-arteriosclerotic actions of HMG-CoA reductase inhibitors in a rat model of chronic inhibition of nitric oxide synthesis. Circ Res 89:415-421, 2001.
44. Palinski W, Tsimikas S: Immunomodulatory effects of statins: mechanisms and potential impact on arteriosclerosis. J Am Soc Nephrol 13:1673-1681, 2002.
45. Pruefer D, Scalia R, Lefer AM: Simvastatin inhibits leukocyte-endothelial cell interactions and protects against inflammatory processes in normocholesterolemic rats. Arterioscler Thromb Vasc Biol 19:2894-2900, 1999.
46. Raabe A, Zimmermann M, Setzer M, Vatter H, Berkefeld S, Seifert V: Effect of intraventricular sodium nitroprusside on cerebral hemodynamics and oxygenation in poor-grade aneurysm patients with severe, medically refractory vasospasm. Neurosurgery 50:1006-1014, 2002.
47. Reiter CD, Gladwin MT: An emerging role for nitric oxide in sickle cell disease vascular homeostasis and therapy. Curr Opin Hematol 10:99-107, 2003.
48. Rosenwasser RH: Re: Safety of intraventricular sodium nitroprusside and thiosulfate for the treatment of cerebral vasospasm in the intensive care unit setting. Stroke 33:1165-1166, 2002 (comment).
49. Rothman K: Matching, in Rothman K (ed): Modern Epidemiology. Boston, Little Brown & Co., 1986, ed 5, vol 1, pp 237-283.
50. Ruigrok YM, Buskens E, Rinkel GJ: Attributable risk of common and rare determinants of subarachnoid hemorrhage. Stroke 32:1173-1175, 2001.
51. Sonmez OF, Unal B, Inaloz S, Sahin B, Yilmaz M, Aydin A, Kaplan S: Therapeutic effects of intracarotid infusion of spermine/nitric oxide complex on cerebral vasospasm. Acta Neurochir (Wien) 144:921-928, 2002.
52. Taddei S, Virdis A, Ghiadoni L, Salvetti A: The role of endothelium in human hypertension. Curr Opin Nephrol Hypertension 7:203-209, 1998.
53. Takemoto M, Liao JK: Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arterioscler Thromb Vasc Biol 21:1712-1719, 2001.
54. Teasdale GM, Murray L: Revisiting the Glasgow Coma Scale and Coma Score. Intensive Care Med 26:153-154, 2000 (comment).
55. Thomas JE, Rosenwasser RH: Reversal of severe cerebral vasospasm in three patients after aneurysmal subarachnoid hemorrhage: Initial observations regarding the use of intraventricular sodium nitroprusside in humans. Neurosurgery 44:48-58, 1999.
56. Thomas JE, Rosenwasser RH, Armonda RA, Harrop J, Mitchell W, Galaria I: Safety of intrathecal sodium nitroprusside for the treatment and prevention of refractory cerebral vasospasm and ischemia in humans. Stroke 30:1409-1416, 1999.
57. Vajkoczy P, Hubner U, Horn P, Bauhuf C, Thome C, Schilling L, Schmiedek P, Quintel M, Thomas JE: Intrathecal sodium nitroprusside improves cerebral blood flow and oxygenation in refractory cerebral vasospasm and ischemia in humans. Stroke 31:1195-1196, 2000.
58. van Swieten JC, Koudstaal PJ, Visser MC, Scheuten HJ, van Gijn J: Interobserver agreement for the assessment of handicap in stroke patients. Stroke 19:604-607, 1988.
59. Vaughan CJ, Delanty N: Neuroprotective properties of statins in cerebral ischemia and stroke. Stroke 30:1969-1973, 1999.
60. Wallerath T, Deckert G, Ternes T, Anderson H, Li H, Witte K, Forstermann U: Resveratrol, a polyphenolic phytoalexin present in red wine, enhances expression and activity of endothelial nitric oxide synthase. Circulation 106:1652-1658, 2002.
61. Woszczyk A, Deinsberger W, Boker DK: Nitric oxide metabolites in cisternal CSF correlate with cerebral vasospasm in patients with a subarachnoid haemorrhage. Acta Neurochir (Wien) 145:257-264, 2003.
62. 2 reactivity in patients. Stroke 34:643-647, 2003.